Financial Results for the Fiscal
Year Ended March 31, 2023 (FY2022)

from the beginning

Financial Results for the Fiscal Year Ended March 31, 2023 (FY2022)

• Safe Harbor for Forward-Looking Statements and Use of Document

• Highlights

• P&L

• Operating Profit Variance Analysis (Q4YTD)

• Guidance (announced in February)Profit Shortfall Causes

• Revenue by Region

• C&V: Continue growth driven by demand increase and new products. Profitability remains good trend

• TMCS: PS continues high growth. Rising material and energy cost, temporal issues in Q4 led profit to decrease

• TBCT: Core business, mainly blood center business continued good trend. Fixed cost for PI increased due to prolonged limited market release

• FY23 Guidance

• FY23 Profitability Improvement Policies

• Profit Variance Analysis (FY23 Guidance)

• Dividend Proposal: Continuous increase per shareholder return policy

Reference

• Revenue by Segment and Region

• Quarterly Trend of Revenue and Operating Profit

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit amount

• CAPEX, Depreciation and R&D Expenses

• Cash Flows (Q4 YTD)

• Cash Flows (Q4)

• Foreign Exchange Sensitivity

• Operating Profit Variance Analysis (Q4)

• Product Pipeline and Major Topics

@

Verification of GS26 Goals Roadmap

• Safe Harbor for Forward-Looking Statements and Use of Document

• 5-Year Financial Targets (FY22 to FY26)

• Awareness of Current Environment

• Confirming Growth Prospects

• C&V growth potential for GS26 achievement

• New Measures to Raise Corporate Value

• Roadmap to Earnings Improvements

• Production transfer to Costa Rica gets results from FY2023

• VC2 Actions and Expected Effects

• TMCS Profitability Improvement Plan

• TBCT Profitability Improvement Plan

@

• Blood and Cell Technologies' core business returned to growth

• Proven Innovation Advancing Source Plasma Industry

• Our Digital Ecosystem and the Impact to Customers

Appendix

• TMCS Profitability Improvement Plan

• TBCT Profitability Improvement Plan

@